News

Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With

  • Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.
    03/17/2024

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates

  • TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago.
    03/06/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

TScan Therapeutics, Inc. (TCRX) can hold. Click on Rating Page for detail.

The price of TScan Therapeutics, Inc. (TCRX) is 7.79 and it was updated on 2024-04-12 13:00:33.

Currently TScan Therapeutics, Inc. (TCRX) is in undervalued.

News
    
News

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

  • All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101
    Mon, Feb. 26, 2024

TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?

  • TScan Therapeutics, Inc. (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
    Mon, Feb. 19, 2024

TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value

  • Prevention relapse data from phase 1 study, using TSC-100/TSC-101 for HLA A*02:01 positive AML, MDS, and ALL patients, is expected to be released in 2024. Results from T-Plex [multiple TCR-Ts] targeting patients' solid tumors in phase 1 study are expected to be released in 2024. Amgen's multi-year collaboration deal brought in an upfront $30 million payment, $500 million possible milestone payments, and tiered royalties; First targeting Crohn's Disease and possibly later Ulcerative Colitis.
    Wed, Dec. 27, 2023

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

  • No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention
    Sat, Dec. 09, 2023

Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why

  • TScan Therapeutics, Inc. (TCRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
    Wed, Dec. 06, 2023
SEC Filings
SEC Filings

TScan Therapeutics, Inc. (TCRX) - S-8

  • SEC Filings
  • 03/06/2024

TScan Therapeutics, Inc. (TCRX) - S-3

  • SEC Filings
  • 03/06/2024

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 02/02/2024

TScan Therapeutics, Inc. (TCRX) - 3

  • SEC Filings
  • 02/02/2024

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 12/21/2023

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 12/18/2023

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 12/08/2023

TScan Therapeutics, Inc. (TCRX) - 3

  • SEC Filings
  • 12/08/2023

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 07/24/2023

TScan Therapeutics, Inc. (TCRX) - 3

  • SEC Filings
  • 07/24/2023

TScan Therapeutics, Inc. (TCRX) - S-8

  • SEC Filings
  • 06/16/2023

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 06/15/2023

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 06/06/2023

TScan Therapeutics, Inc. (TCRX) - 3

  • SEC Filings
  • 06/05/2023

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 06/02/2023

TScan Therapeutics, Inc. (TCRX) - 3

  • SEC Filings
  • 06/02/2023

TScan Therapeutics, Inc. (TCRX) - FWP

  • SEC Filings
  • 05/26/2023

TScan Therapeutics, Inc. (TCRX) - AW

  • SEC Filings
  • 05/16/2023

TScan Therapeutics, Inc. (TCRX) - ARS

  • SEC Filings
  • 04/25/2023

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 04/10/2023

TScan Therapeutics, Inc. (TCRX) - 3

  • SEC Filings
  • 04/10/2023

TScan Therapeutics, Inc. (TCRX) - S-8

  • SEC Filings
  • 03/08/2023

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 02/06/2023

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 12/29/2022

TScan Therapeutics, Inc. (TCRX) - S-3

  • SEC Filings
  • 11/09/2022

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 07/27/2022

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 07/07/2022

TScan Therapeutics, Inc. (TCRX) - 3

  • SEC Filings
  • 07/07/2022

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 06/03/2022

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 05/20/2022

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 05/12/2022

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 03/28/2022

TScan Therapeutics, Inc. (TCRX) - S-8

  • SEC Filings
  • 03/09/2022

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 01/20/2022

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 12/27/2021

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 09/27/2021

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 09/22/2021

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 09/13/2021

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 09/09/2021

TScan Therapeutics, Inc. (TCRX) - 3

  • SEC Filings
  • 09/09/2021

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 08/31/2021

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 07/22/2021

TScan Therapeutics, Inc. (TCRX) - S-8

  • SEC Filings
  • 07/16/2021

TScan Therapeutics, Inc. (TCRX) - FWP

  • SEC Filings
  • 07/16/2021

TScan Therapeutics, Inc. (TCRX) - 4

  • SEC Filings
  • 07/16/2021

TScan Therapeutics, Inc. (TCRX) - 3

  • SEC Filings
  • 07/15/2021

TScan Therapeutics, Inc. (TCRX) - S-1

  • SEC Filings
  • 04/23/2021

TScan Therapeutics, Inc. (TCRX) - DRS

  • SEC Filings
  • 03/19/2021

TScan Therapeutics, Inc. (TCRX) - D

  • SEC Filings
  • 01/28/2021

TScan Therapeutics, Inc. (TCRX) - D

  • SEC Filings
  • 07/26/2019
Press Releases
StockPrice Release
More Headlines
News

Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect?

  • The mean of analysts' price targets for TScan Therapeutics, Inc. (TCRX) points to a 62.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  • 12/01/2023

TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy?

  • Does TScan Therapeutics, Inc. (TCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
  • 11/27/2023

TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why

  • TScan Therapeutics, Inc. (TCRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
  • 11/20/2023

What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock

  • TScan Therapeutics, Inc. (TCRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  • 11/15/2023

TScan Therapeutics: That Recent Amgen Deal Is The Only Point Of Interest

  • TScan Therapeutics is developing TCR T-cell therapies for cancer using a transposon-based T cell engineering method. The company aims to target a broader patient population by addressing a wide range of human leukocyte antigen (HLA) types. TScan has a partnership with Amgen and has a sufficient cash balance to last for 6-7 quarters.
  • 10/14/2023

TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why

  • TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
  • 10/12/2023

TScan Therapeutics to Participate in Upcoming Investor Conferences

  • WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences:
  • 09/05/2023

TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know

  • TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  • 08/16/2023

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

  • TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.63 per share a year ago.
  • 08/10/2023

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

  • Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation
  • 05/17/2023

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

  • TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.67 per share a year ago.
  • 05/10/2023

3 Top Strategies for Maximizing Penny Stock Profits Right Now

  • Use these strategies to maximize your penny stocks profits The post 3 Top Strategies for Maximizing Penny Stock Profits Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 05/10/2023

TScan Therapeutics stock soars after Amgen collaboration on Crohn's disease treatment that could bring in more than $500 million

  • Shares of TScan Therapeutics Inc. TCRX powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration with Amgen Inc. AMGN to treat Crohn's disease that could be worth more than $500 million to TScan. Amgen shares slipped 0.1% ahead of the open.
  • 05/09/2023

TScan Therapeutics to Participate in the Barclays Global Healthcare Conference

  • WALTHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the Barclays Global Healthcare Conference being held at the Loews Miami Beach Hotel in Miami Beach, FL on Wednesday, March 15, 2023 at 4:05 p.m. Eastern Time.
  • 03/13/2023

TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference

  • WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023, at 3:30 p.m. Eastern Time.
  • 02/21/2023

Best Penny Stocks To Buy? 5 To Watch After Big News This Week

  • Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?
  • 01/23/2023

TScan Therapeutics to Participate in Upcoming Investor Conferences

  • WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences:
  • 09/22/2022

TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

  • WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference being held at the Sheraton New York in New York, NY on Wednesday, September 14, 2022 at 12:55 p.m. ET.
  • 09/07/2022

TScan Therapeutics to Participate in Upcoming Investor Conferences

  • WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
  • 03/02/2022

TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference

  • WALTHAM, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 12:00 p.m. Eastern Time.
  • 02/10/2022

FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies

  • The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies patients undergoing allogeneic hematopoietic cell transplantation (HCT).  The target of TSC-100 is the minor histocompatibility antigen HA-1, which is a lineage-specific antigen found on blood cells.
  • 01/24/2022

TScan Therapeutics to Participate in Upcoming Investor Conferences

  • WALTHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate virtually at the following upcoming investor conferences:
  • 11/11/2021

Wall Street Analysts Believe TScan Therapeutics, Inc. (TCRX) Could Rally 147%: Here's is How to Trade

  • The mean of analysts' price targets for TScan Therapeutics, Inc. (TCRX) points to a 147.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  • 11/01/2021

TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations

  • WALTHAM, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Heather Savelle as Vice President, Investor Relations. Ms. Savelle brings to TScan over 20 years of experience in corporate communications and investor relations.
  • 10/05/2021

TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference

  • WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:00 p.m. ET.
  • 09/28/2021

TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer

  • WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that Zoran Zdraveski, J.D., Ph.D. has been appointed as Chief Legal Officer.
  • 09/09/2021

TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

  • WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 4:15 p.m. ET.
  • 09/02/2021

TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

  • Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs
  • 08/19/2021
Unlock
TCRX Ratings Summary
TCRX Quant Ranking